全文获取类型
收费全文 | 654篇 |
免费 | 57篇 |
国内免费 | 14篇 |
学科分类
医药卫生 | 725篇 |
出版年
2023年 | 1篇 |
2022年 | 9篇 |
2021年 | 9篇 |
2020年 | 14篇 |
2019年 | 16篇 |
2018年 | 15篇 |
2017年 | 24篇 |
2016年 | 18篇 |
2015年 | 21篇 |
2014年 | 32篇 |
2013年 | 71篇 |
2012年 | 44篇 |
2011年 | 42篇 |
2010年 | 36篇 |
2009年 | 49篇 |
2008年 | 51篇 |
2007年 | 52篇 |
2006年 | 30篇 |
2005年 | 46篇 |
2004年 | 30篇 |
2003年 | 29篇 |
2002年 | 29篇 |
2001年 | 23篇 |
2000年 | 8篇 |
1999年 | 4篇 |
1998年 | 3篇 |
1997年 | 6篇 |
1995年 | 2篇 |
1993年 | 1篇 |
1990年 | 2篇 |
1988年 | 3篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1980年 | 1篇 |
1977年 | 1篇 |
1969年 | 1篇 |
排序方式: 共有725条查询结果,搜索用时 15 毫秒
41.
沙利度胺及其衍生物临床及作用机制研究进展 总被引:3,自引:2,他引:3
沙利度胺是一种合成的谷氨酸衍生物,原作为镇静剂治疗早孕反应,20世纪60年代出现严重的致胎儿缺陷而被禁止使用。但此后研究发现,沙利度胺具有免疫调节和抗血管生成作用,治疗多发性骨髓瘤等恶性肿瘤以及其他难治性疾病有效。通过对沙利度胺进行结构改造得到的一系列免疫调节药克服了原形药物的严重不良反应,这些药物的强大的抗癌作用意味着它们将走出沙利度胺的阴影,成为有效的抗肿瘤药物。现对沙利度胺及其衍生物的临床应用和作用机制的研究进展进行综述。 相似文献
42.
反应停联合化疗治疗难治及复发性多发性骨髓瘤疗效观察及治疗前后VEGF变化 总被引:1,自引:1,他引:1
目的观察反应停联合VAD方案治疗难治及复发性多发性骨髓瘤的临床疗效并测定反应停治疗前后血清VEGF水平的变化。方法反应停剂量为400 ̄600mg/d,每5周联合VAD方案治疗难治及复发性多发性骨髓瘤28例。有效病例治疗前和治疗后12周测定血清中VEGF水平。结果总有效率89.3%,完全缓解率14.3%;其中25例有效患者治疗前血清VEGF水平为(326.00±33.67)ng/L,治疗后12周血清VEGF水平为(84.00±40.26)ng/L(P<0.01)。结论反应停联合VAD方案为治疗难治性复发性多发性骨髓瘤较好的选择,反应停可明显降低MM患者血清VEGF水平。 相似文献
43.
The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. 总被引:1,自引:0,他引:1
Thalidomide has shown efficacy in relapsed or refractory patients of multiple myeloma (MM). We present the adverse effect profile of thalidomide in 23 relapsed or refractory MM patients treated with this drug over a period of 15 months. Constipation (100% incidence) and sedation (87%) were the most common adverse effects. Neuropathy had low incidence and was late in onset (>12 months). Tolerance developed to sedation, constipation and skin lesions. All the adverse drug reactions were tolerable and did not warrant decrease or termination of therapy, except for peripheral neuropathy. Contrary to Western reports, peripheral neuropathy in Indian patients developed at a cumulative dose of 200 g or more after 10 months or more of therapy. Therapy was discontinued in one patient due to marked elevation of liver enzyme that was later attributed to acute hepatitis C infection. Only one patient dropped out of the trial for unknown reasons. Overall, thalidomide was found to be a relatively safe drug that can be used over a prolonged period of time. 相似文献
44.
A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma 总被引:9,自引:0,他引:9
OBJECTIVE: To conduct a dose-finding trial using a single low dose and dose escalation of a higher dose of thalidomide in patients with metastatic renal cell carcinoma (RCC), and to evaluate the antineoplastic effectiveness of thalidomide as an anti-angiogenic agent on RCC. PATIENTS AND METHODS: The 14 patients enrolled in the study had progressive measurable metastatic RCC and consented to participate. Patients were randomized to either a fixed low dose of 200 mg of thalidomide or to a high dose of 800 mg that was increased to a maximum dose of 1200 mg daily. Patients were evaluated for response after 8 weeks of therapy. RESULTS: Stable disease was achieved in six patients and was seen in both the low-dose and high-dose thalidomide groups. The median overall survival was 9 months. The low-dose thalidomide regimen was better tolerated and patients survived longer than those on the high-dose regimen (16 vs 6 months, P = 0.04) CONCLUSION: The use of low-dose thalidomide in patients with metastatic RCC was well tolerated and they survived for longer than those on the high-dose regimen. 相似文献
45.
Lima V Brito GA Cunha FQ Rebouças CG Falcão BA Augusto RF Souza ML Leitão BT Ribeiro RA 《European journal of oral sciences》2005,113(3):210-217
Oral mucositis is a frequent side-effect of cancer therapy. A definitive method of prophylaxis or treatment is not yet available. As pentoxifylline (PTX) and thalidomide (TLD) have been shown to inhibit cytokine synthesis, we studied the effects of these cytokine inhibitors in an experimental oral mucositis model. Oral mucositis was induced in Golden hamsters by the administration of 5-fluorouracil (5-FU) followed by mechanical trauma of the cheek pouch. On days 4, 5, 10, 12, 14 and 16, lesions induced by 5-FU were examined macroscopically and microscopically, and the presence and intensity of hyperemia, erythema, edema, inflammatory cell infiltration, hemorrhagic areas, ulcers and abscesses were recorded. Saline (control), PTX (5, 15, 45 mg kg(-1)) or TLD (10, 30, 90 mg kg(-1)) were administered daily and animals were killed on day 10 for macroscopic and histological analysis and assay of myeloperoxidase (MPO) activity. Animals were weighed daily, and total and differential leukocyte counts were performed on peripheral blood. PTX and TLD were found to reduce the macroscopic and histological parameters of oral mucositis and MPO activity. PTX and TLD also reversed peripheral neutrophilia, but only PTX prevented weight loss. The results indicate a protective effect of PTX and TLD, suggesting an important role for tumour necrosis factor-alpha (TNF-alpha) in the pathophysiology of 5-FU induced-oral mucositis in hamsters. 相似文献
46.
Ozanic Bulic S Fassihi H Mellerio JE McGrath JA Atherton DJ 《The British journal of dermatology》2005,152(6):1332-1334
Epidermolysis bullosa (EB) pruriginosa is a distinctive clinical subtype of dystrophic EB. We report a patient with dominant dystrophic EB pruriginosa, who had an excellent response to systemic thalidomide treatment. The mechanism of action of thalidomide in the management of pruriginous disorders is not yet completely understood. Most recent studies point towards an immunomodulatory action of thalidomide that may suppress excessive production of tumour necrosis factor-alpha and may downregulate certain cell surface adhesion molecules involved in leucocyte migration. 相似文献
47.
Thalidomide for the treatment of multiple myeloma 总被引:5,自引:0,他引:5
Although thalidomide was withdrawn in the 1960s after its teratogenic property was recognized, it was subsequently found that this drug possesses immunomodulatory and anti-inflammatory effects. Recent studies have also demonstrated that thalidomide has antineoplastic activity via an antiangiogenic mechanism. Observations in the late 1990s that the microenvironment in the bone marrow plays a role in tumor progression in multiple myeloma provided an impetus to use thalidomide for the treatment of this disease. It is known that thalidomide monotherapy is effective in one-third of refractory cases, and in combination with glucocorticoids and/or antineoplastic drugs, thalidomide provides a response rate of more than 50%. Thus, thalidomide therapy is considered a standard approach for the treatment of relapsed and refractory myeloma. The exact mechanism of the antimyeloma effect of thalidomide is not yet clearly understood. Anti-angiogenic effects, direct activity in tumor cells such as the induction of apoptosis or G1 arrest of the cell cycle, the inhibition of growth factor production, the regulation of interactions between tumor and stromal cells, and the modulation of tumor immunity have been considered as possible mechanisms. In addition to its teratogenicity, the adverse effects of thalidomide have been general symptoms such as somnolence and headache, peripheral neuropathy, constipation, skin rash, and other symptoms. Although these adverse effects are generally reversible and mild, grade 3 and 4 toxicities such as peripheral neuropathy, deep venous thrombosis, neutropenia, and toxic dermal necrosis have occasionally been reported. The application of thalidomide therapy in patients with multiple myeloma is being broadened to include not only cases of refractory myeloma, but also previously untreated cases, as well as for maintenance therapy after hematopoietic stem cell transplantation and for the treatment of other hematological diseases. The safe use of this drug will depend on the establishment of diagnostic and treatment guidelines. In addition, the establishment of a nation-wide regulation system is urgently needed in Japan. 相似文献
48.
Bartlett JB Michael A Clarke IA Dredge K Nicholson S Kristeleit H Polychronis A Pandha H Muller GW Stirling DI Zeldis J Dalgleish AG 《British journal of cancer》2004,90(5):955-961
We assessed the safety, tolerability and efficacy of the immunomodulatory drug, CC-5013 (REVIMID trade mark ), in the treatment of patients with metastatic malignant melanoma and other advanced cancers. A total of 20 heavily pretreated patients received a dose-escalating regimen of oral CC-5013. Maximal tolerated dose, toxicity and clinical responses were evaluated and analysis of peripheral T-cell surface markers and serum for cytokines and proangiogenic factors were performed. CC-5013 was well tolerated. In all, 87% of adverse effects were classified as grade 1 or grade 2 according to Common Toxicity Criteria and there were no serious adverse events attributable to CC-5013 treatment. Six patients failed to complete the study, three because of disease progression, two withdrew consent and one was entered inappropriately and withdrawn from the study. The remaining 14 patients completed treatment without dose reduction, with one patient achieving partial remission. Evidence of T-cell activation was indicated by significantly increased serum levels of sIL-2 receptor, granulocyte-macrophage colony-stimulating factor, interleukin-12 (IL-12), tumour necrosis factor-alpha and IL-8 in nine patients from whom serum was available. However, levels of proangiogenic factors vascular endothelial growth factor and basic foetal growth factor were not consistently affected. This study demonstrates the safety, tolerability and suggests the clinical activity of CC-5013 in the treatment of refractory malignant melanoma. Furthermore, this is the first report demonstrating T-cell stimulatory activity of this class of compound in patients with advanced cancer. 相似文献
49.
Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma 总被引:4,自引:0,他引:4
Arrieta O Guevara P Tamariz J Rembao D Rivera E Sotelo J 《International journal of experimental pathology》2002,83(2):99-104
Thalidomide could have therapeutic applications in neoplasms and in other diseases, particularly those of autoimmune origin. The objective of this study was to investigate the effect of various doses of thalidomide on the growth of C6 glioma in rats, and to determine its effects on parameters of cell proliferation and angiogenesis. Additionally, we investigated a potential enhancement of the antitumoral action of thalidomide when combined with a low dose of the antineoplastic carmustine. C6 glioma cells were implanted subcutaneously in Wistar rats. A highly malignant glioma developed in 80% of animals. When the tumour reached 2.0 cm diameter thalidomide was administered at doses of 100, 200 or 400 mg/kg/day. When given at a dose of 400 mg/kg/day thalidomide significantly reduced the tumour volume, the mitotic index and cell proliferation but not the vascular density. The combination of thalidomide plus carmustine increased the inhibitory effect on tumoral growth. Our results indicate that thalidomide is effective against malignant glioma; apparently by an antiproliferative effect, rather than by inhibition of angiogenesis; when combined with carmustine it could increase the response of glioma to antineoplastic treatment. 相似文献